10.02.2011 • News

Sanofi CEO Says Genzyme Offer May Be Extended

Sanofi Aventis Chief Executive Chris Viehbacher said in an interview that the French pharmaceuticals group's offer for Genzyme could be extended for a third time, beyond the Feb. 15 deadline.

Asked by La Tribune newspaper about the deadline, Viehbacher said: "It is a possibility, there are no limits on takeover offers in the United States."

He added: "It is normal to spend time on an operation of $18.5 billion."

Viehbacher's interview is to be published in La Tribune business newspaper on Thursday and was made available late on Wednesday.

From Lab to Market Challenge

Vote Now: Germany's Most Promising Chemistry Start-ups
Choose your favourite among the finalists

Vote Now: Germany's Most Promising Chemistry Start-ups

The "From Lab to Market Challenge" brings together the most promising founders from chemistry, materials science, and industrial biotechnology. Starting June 1st, you can cast your public vote for the finalists on CHEManager.com — before the award ceremony with €10,000 in prizes takes place on June 25th.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Top-Feature

most read

Photo
News • Chemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.